Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verzistobart - Agenus

Next Previous
Search
Drug Profile

Verzistobart - Agenus

Alternative Names: Anti-TIM-3 monoclonal antibody - Agenus; INCAGN-02390; INCAGN-2390

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus; Ludwig Institute for Cancer Research
  • Developer Agenus; Incyte Corporation; University of Washington
  • Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Squamous cell cancer
  • Phase I/II Malignant melanoma; Solid tumours
  • Phase I Merkel cell carcinoma
  • No development reported Cancer

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 19 Oct 2023 Phase-I clinical trials in Merkel cell carcinoma (Late-stage disease, Second-line therapy or greater, Combination therapy, Refractory metastatic disease) in USA (IV) (NCT06056895)
  • 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Solid tumours and Malignant melanoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top